These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32342632)

  • 1. Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR.
    Kramer CSM; Franke-van Dijk MEI; Bakker KH; Uyar-Mercankaya M; Karahan GE; Roelen DL; Claas FHJ; Heidt S
    Am J Transplant; 2020 Dec; 20(12):3341-3353. PubMed ID: 32342632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Evaluation of the Antibody-Verified Status of Eplets Listed in the HLA Epitope Registry.
    Bezstarosti S; Bakker KH; Kramer CSM; de Fijter JW; Reinders MEJ; Mulder A; Claas FHJ; Heidt S
    Front Immunol; 2021; 12():800946. PubMed ID: 35154076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DQ-Specific Recombinant Human Monoclonal Antibodies Allow for In-Depth Analysis of HLA-DQ Epitopes.
    Bezstarosti S; Kramer CSM; Franke-van Dijk MEI; Vergunst M; Bakker KH; Uyar-Mercankaya M; Buchli R; Roelen DL; de Fijter JW; Claas FHJ; Heidt S
    Front Immunol; 2021; 12():761893. PubMed ID: 35069533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.
    Duquesnoy RJ; Awadalla Y; Lomago J; Jelinek L; Howe J; Zern D; Hunter B; Martell J; Girnita A; Zeevi A
    Transpl Immunol; 2008 Feb; 18(4):352-60. PubMed ID: 18158123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplet Mismatch Load and
    Senev A; Coemans M; Lerut E; Van Sandt V; Kerkhofs J; Daniëls L; Driessche MV; Compernolle V; Sprangers B; Van Loon E; Callemeyn J; Claas F; Tambur AR; Verbeke G; Kuypers D; Emonds MP; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2193-2204. PubMed ID: 32764139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation.
    Otten HG; Calis JJ; Keşmir C; van Zuilen AD; Spierings E
    Hum Immunol; 2013 Mar; 74(3):290-6. PubMed ID: 23232063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of molecular matching in transplantation requires further characterization of both immunogenicity and antigenicity of individual HLA epitopes.
    Bezstarosti S; Kramer CSM; Claas FHJ; de Fijter JW; Reinders MEJ; Heidt S
    Hum Immunol; 2022 Mar; 83(3):256-263. PubMed ID: 34963506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens.
    Duquesnoy RJ; Marrari M
    Tissue Antigens; 2009 Aug; 74(2):117-33. PubMed ID: 19497041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss.
    Sapir-Pichhadze R; Zhang X; Ferradji A; Madbouly A; Tinckam KJ; Gebel HM; Blum D; Marrari M; Kim SJ; Fingerson S; Bashyal P; Cardinal H; Foster BJ
    Kidney Int; 2020 Apr; 97(4):778-785. PubMed ID: 32059998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First report on the antibody verification of HLA-ABC epitopes recorded in the website-based HLA Epitope Registry.
    Duquesnoy RJ; Marrari M; Mulder A; Sousa LC; da Silva AS; do Monte SJ
    Tissue Antigens; 2014 Jun; 83(6):391-400. PubMed ID: 24828056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations between Terasaki's HLA class II epitopes and HLAMatchmaker-defined eplets on HLA-DR and -DQ antigens.
    Marrari M; Duquesnoy RJ
    Tissue Antigens; 2009 Aug; 74(2):134-46. PubMed ID: 19497040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First report on the antibody verification of HLA-DR, HLA-DQ and HLA-DP epitopes recorded in the HLA Epitope Registry.
    Duquesnoy RJ; Marrari M; Tambur AR; Mulder A; Sousa LC; da Silva AS; do Monte SJ
    Hum Immunol; 2014 Nov; 75(11):1097-103. PubMed ID: 25305456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matchmaker, matchmaker make me a match: Opportunities and challenges in optimizing compatibility of HLA eplets in transplantation.
    Lemieux W; Mohammadhassanzadeh H; Klement W; Daniel C; Sapir-Pichhadze R
    Int J Immunogenet; 2021 Apr; 48(2):135-144. PubMed ID: 33426788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural aspects of human leukocyte antigen class I epitopes detected by human monoclonal antibodies.
    Duquesnoy RJ; Marrari M; Mulder A; Claas FH; Mostecki J; Balazs I
    Hum Immunol; 2012 Mar; 73(3):267-77. PubMed ID: 22227099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
    Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
    Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward defining the immunogenicity of HLA epitopes: Impact of HLA class I eplets on antibody formation during pregnancy.
    Hönger G; Niemann M; Schawalder L; Jones J; van Heck MR; van de Pasch LAL; Vendelbosch S; Rozemuller EH; Hösli I; Blümel S; Schaub S
    HLA; 2020 Nov; 96(5):589-600. PubMed ID: 32829523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA graph, a free and ready-to-use bioinformatics tool to explore anti-HLA eplets reactivity pattern.
    Usureau C; Jacob V; Dubois V; Masson D; Jollet I; Desoutter J; Taupin JL; Guillaume N
    HLA; 2022 Sep; 100(3):244-253. PubMed ID: 35672253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of epitopes on HLA-DRB alleles reacting with antibodies in sera from women sensitized during pregnancy.
    Duquesnoy RJ; Hönger G; Hösli I; Marrari M; Schaub S
    Hum Immunol; 2016 Feb; 77(2):214-22. PubMed ID: 26686763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.
    Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A
    Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients.
    Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K
    Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.